Financial Performance - Total revenue for the six months ended June 30, 2022, was HKD 93,979,000, a decrease of 9.4% from HKD 103,275,000 in the same period of 2021[13] - Gross profit for the same period was HKD 39,933,000, down 26.2% from HKD 54,058,000 year-on-year[13] - The company reported a loss before tax of HKD 120,432,000, compared to a profit of HKD 58,235,000 in the previous year[13] - The total comprehensive loss for the period was HKD 142,457,000, compared to a comprehensive income of HKD 65,279,000 in the same period last year[13] - For the six months ended June 30, 2022, the company reported a loss attributable to equity holders of HKD 97,017,000, compared to a profit of HKD 60,666,000 in the same period of 2021, representing a significant decline[14] - The total comprehensive loss attributable to equity holders for the same period was HKD 120,127,000, compared to a total comprehensive income of HKD 66,496,000 in 2021[14] - Basic and diluted loss per share for the six months ended June 30, 2022, was HKD 1.92, a decrease from earnings of HKD 1.20 per share in the prior year[14] Assets and Liabilities - As of June 30, 2022, non-current assets totaled HKD 333,981,000, down from HKD 395,499,000 as of December 31, 2021, indicating a decrease of approximately 15.5%[16] - Current assets decreased to HKD 506,324,000 from HKD 575,834,000, reflecting a decline of about 12.0%[16] - The company's total liabilities increased to HKD 272,259,000 from HKD 261,991,000, showing a rise of approximately 3.9%[17] - The net asset value as of June 30, 2022, was HKD 542,033,000, down from HKD 682,844,000 at the end of 2021, representing a decrease of about 20.6%[17] - The company reported a decrease in cash and cash equivalents to HKD 202,447,000 from HKD 259,264,000, a decline of approximately 22.0%[16] - The company’s total equity attributable to equity holders was HKD 532,636,000, down from HKD 651,117,000, indicating a decrease of about 18.2%[17] Operational Segments - Total revenue generated from external customers was HKD 93,979 thousand, with the dental business contributing HKD 87,658 thousand[28] - The operating loss for the health and rehabilitation segment was HKD (3,678) thousand, while the health and wellness segment reported an operating loss of HKD (28,307) thousand[28] - The company has expanded its operational segments to include health and wellness, with new projects in Zhuhai and Shanghai commencing operations[28] - The segment profit before depreciation and amortization for the health rehabilitation segment was HKD 15,280,000, while the health maintenance segment reported a profit of HKD 45,829,000, leading to a total segment profit of HKD 55,370,000[53] Cash Flow - For the six months ended June 30, 2022, the net cash used in operating activities was HKD (51,669) thousand, compared to HKD 52,320 thousand for the same period in 2021[21] - The net cash generated from investing activities was HKD 6,314 thousand, a decrease from HKD 8,842 thousand in the previous year[21] - The net cash used in financing activities was HKD (6,322) thousand, compared to HKD (4,273) thousand in the same period last year[21] Research and Development - Research and development expenses for the period were HKD 10,000,000, an increase from HKD 8,892,000 in the previous year, reflecting a growth of approximately 12.4%[65] - The company applied for 9 new patents as part of its ongoing expansion of the implant research and development team[156] - Government grants and other income related to training consultations for research and development were approximately HKD 1.2 million for the six months ended June 30, 2022[156] Market and Strategic Outlook - Future outlook remains cautious due to ongoing market challenges and the need for strategic adjustments[13] - The company is actively adjusting its marketing strategies in response to significant impacts from the COVID-19 pandemic on customer orders[152] - The company plans to expand its dental business by increasing sales networks both domestically and internationally, particularly in the U.S.[163] - The dental market in China is expected to have significant growth potential, with the company aiming to enhance its product offerings and market presence[163] Impairment and Losses - The company experienced a significant loss in fair value changes of financial assets amounting to HKD 13,891,000, compared to a gain of HKD 47,609,000 in the previous year[13] - The impairment loss on trade receivables was HKD 1,666,000, compared to a reversal of HKD 138,000 in the previous year[13] - Impairment losses of approximately HKD 45,300,000 were recognized for right-of-use assets, properties, and equipment in the health business segment for the same period[157] Shareholder Information - The company has not declared or recommended any dividends for the six months ended June 30, 2022[70] - The average number of ordinary shares in issue during the period remained unchanged at 5,042,139,374 shares[73] - The company recognized share-based payment expenses of HKD 1,646,000 for the six months ended June 30, 2022, compared to HKD 3,600,000 for the same period in 2021[131] Employment and Staff - The group employed approximately 800 staff as of June 30, 2022, an increase from approximately 700 staff as of December 31, 2021[183]
佳兆业健康(00876) - 2022 - 中期财报